ASCO® GI 2024 Insights: "Bi-Weekly FTD/TPI + Bevacizumab vs. FTD/TPI Monotherapy for Chemorefractory mCRC"

55 views
February 12, 2024
Comments 0
Login to view comments. Click here to Login